Onderzoeker
Guido Vanham
Affiliaties
- Virologie (Onderzoekseenheid)
Lid
Vanaf1 jan 1989 → 30 jul 2019
Projecten
1 - 10 of 19
- Machine learning framework voor T-cell receptor repertoiregebaseerde virale diagnostiekVanaf3 nov 2020 → Heden
- Evaluation of the role of immune checkpoint molecules in the natural killer cell-mediated anti-HIV responseVanaf11 apr 2019 → Heden
- Ontwikkeling van een nieuwe nanopartikel-formulatie voor een therapeutisch vaccin gebasseerd op mRNA tegen HIVVanaf11 apr 2019 → Heden
- Immuno Cytometry : Phenotyping immune cellular components, in the context of HBV, HIV and AD, by new, advanced technologiesVanaf18 jan 2018 → 17 aug 2020
- Interventions towards a functional cure: detailed phenotyping of the HIV-specific polyfunctional CD8+ T cell responses of controllersVanaf24 jun 2016 → 12 feb 2020
- Search for host genetic factors associated with neurological complications (HAM/TSP) in Peruvian HTLV-1 infected individualsVanaf18 mei 2016 → 27 sep 2016
- Rationeel ontwerp van een therapeutisch vaccin tegen HIV-1 gebaseerd op een nieuwe formulering van nanopartikelVanaf1 jan 2016 → 31 dec 2020
- Cell-associated HIV-RNA as a superior marker of treatment success or failureVanaf29 apr 2015 → 19 sep 2019
- Therapeutic TriMix/Mrna BASED Vaccine in Chronic HIV-1 Infected Patients Receiving Antiretroviral TherapyVanaf1 dec 2013 → 31 dec 2017
- Inductie van breed-potente Hiv-1 suppressieve immuun responsen door dendritische cellen opgeladen met gag mRNA.Vanaf1 jan 2011 → 21 mrt 2019
Publicaties
31 - 40 van 205
- 2,6-Di(arylamino)-3-fluoropyridine derivatives as HIV non-nucleoside reverse transcriptase inhibitors(2016)
Auteurs: Sergey Sergeyev, Ashok Kumar Yadav, Philippe Franck, J Michiels, Paul Lewi, Jan Heeres, Guido Vanham, Kevin Ariën, Christophe M L Vande Velde, Hans De Winter, et al.
Pagina's: 1854-1868 - A cross-sectional analysis of selected genital tract immunological markers and molecular vaginal microbiota in Sub-Saharan African women with relevance to HIV risk and prevention(2015)
Auteurs: J.K. Kyongo, Tania Crucitti, Joris Menten, Liselotte Hardy, Piet Cools, J Michiels, Sinead Delany-Moretlwe, Mary Mwaura, Gilles Ndayisaba, Sarah Joseph, et al.
Pagina's: 526-538 - Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques(2014)
Auteurs: C Moog, N. Dereuddre-Bosquet, J-L Teillaud, M E Biedma, V Holl, G Vanham, Leo Heyndrickx, A Van Dorsselaer, D Katinger, B Vcelar, et al.
Pagina's: 46-56 - Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1(2014)
Auteurs: Carolien Grammen, Kevin Ariën, Muthusamy Venkatraj, Jurgen Joossens, Pieter Van der Veken, Jan Heeres, Paul J Lewi, Steven Haenen, Koen Augustyns, Guido Vanham, et al.
Pagina's: 113-121 - From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds(2014)
Auteurs: Muthusamy Venkatraj, Kevin Ariën, Jan Heeres, Jurgen Joossens, Bertrand Dirié, Sophie Lyssens, J Michiels, Paul Cos, Paul J Lewi, Guido Vanham, et al.
Pagina's: 5241-5248 - What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?(2014)
Auteurs: G Vanham, Anne Buvé, Eric Florence, Carole Seguin-Devaux, Asier Sáez-Cirión
Pagina's: 603-605 - Challenges and advances towards the rational design of mRNA vaccines(2013)
Auteurs: Charlotte Pollard, S. De Koker, X. Saelens, G Vanham, J. Grooten
Pagina's: 705-713 - Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate(2013)
Auteurs: M.L. Visciano, M. Tagliamonte, G. Stewart-Jones, Leo Heyndrickx, G Vanham, M. Jansson, A. Fomsgaard, B. Grevstad, M. Ramaswamy, F.M. Buonaguro, et al.
Pagina's: 1-11 - The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody(2013)
Auteurs: S. Balla-Jhagjhoorsingh, D. Corti, Leo Heyndrickx, Betty Willems, K Vereecken, D. Davis, G Vanham
Pagina's: e68863 - Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines(2013)
Auteurs: Charlotte Pollard, J Rejman, Winni De Haes, B. Verrier, E. Van Gulck, T. Naessens, S. De Smedt, P. Bogaert, J. Grooten, G Vanham, et al.
Pagina's: 251-259